苏州富士莱医药股份有限公司 投资者关系活动记录表 证券代码：301258 证券简称：富士莱 编号：20220712 | --- | --- | --- | |-------------------------|-----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | √特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | □分析师会议 \n□业绩说明会 \n□路演活动 \n□其他 | | 参与单位名称及 人员姓名 | 中泰证券 李建 | | | 时间 | 2022 年 07 月 12 | 日（周二） 15:30-16:00 | | 地点 | 公司会议室 | | | 上市公司接待人 员姓名 | ...

苏州富士莱医药股份有限公司 投资者关系活动记录表 证券代码：301258 证券简称：富士莱 编号：20220726 | --- | --- | --- | |-------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | √特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | □分析师会议 \n □业绩说明会 \n □路演活动 \n □其他 | | 参与单位名称及 人员姓名 | ...

苏州富士莱医药股份有限公司 投资者关系活动记录表 证券代码：301258 证券简称：富士莱 编号：20220725 | --- | --- | |-------------------------|-------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | √特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n□现场参观 □其他 | | 参与单位名称及 人员姓名 | 金百镕投资 周枫、马学进 | | 时间 | 月 日（周一） | | | 07 25 15:00-15:30 | | 地点 | 公司董事长办公室 | | | 董事长、总经理：钱祥云 | | 上市公司接待人 员姓名 | 董事会秘书、董事、副总经理：卞爱进 证券事务代表：吴晨钧 | | | 投资者提问及回复列示如下： | | | 、公司 2022 年 Q1 收入同比增长 20% 以上，硫辛酸同比提价的 贡献幅度有多大？销 ...

苏州富士莱医药股份有限公司 投资者关系活动记录表 证券代码：301258 证券简称：富士莱 编号：20220808 | --- | --- | --- | |-----------------------|-----------------------------------------------------|--------------------------------------------------------------| | 投资者关系活动 \n类别 | √特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | □分析师会议 \n □业绩说明会 \n □路演活动 \n □其他 | | 参与单位名称及 | 民生医药 许睿 | | | 人员姓名 | | | | 时间 | 2022 年 08 月 08 | 日（周一） 15:00-15:30 | | 地点 | 腾讯会议 | | | 上市公司接待人 | 董事会秘书、董事、副总经理：卞爱进 | | | 员姓名 | | | | | 投资者提问及回复列示如下： | | | | 1 何？？ | 、请问硫辛酸目前市场上的生产厂家有哪些？未来竞争格局如 ...

苏州富士莱医药股份有限公司 投资者关系活动记录表 证券代码：301258 证券简称：富士莱 编号：20220708 | --- | --- | --- | |-------------------------|-----------------------------------------------------|--------------------------------------------------------------| | 投资者关系活动 \n类别 | √特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | □分析师会议 \n □业绩说明会 \n □路演活动 \n □其他 | | 参与单位名称及 人员姓名 | 德福资本 | 朱柏力、裴彦春 | | 时间 | 2022 年 07 月 07 | 日（周四） 10:00-11:00 | | 地点 | 公司董事长办公室 | | | 上市公司接待人 员姓名 | 董事长、总经理：钱祥云 证券事务代表：吴晨钧 | 董事会秘书、董事、副总经理：卞爱进 | | | | 投资者提问及回复列示如下： | | | 1 么？ | 、请介绍公司产品的应 ...

Group 1: Investor Relations Activity - The activity type is a specific object survey [1] - Participants include representatives from Dongfang Medicine and Wanjia Fund [1] - The meeting took place on August 3, 2022, from 9:00 to 9:30 AM via Tencent Meeting [1] Group 2: Key Questions and Responses - Inquiry about the price difference between pharmaceutical intermediates and health product raw materials [1] - Response indicates that the current designed production capacity is 50 tons per year for the raw material drug alpha-lipoic acid [1] - Price differences are minimal, primarily influenced by country regulations, product usage, and customer demand [1]

苏州富士莱医药股份有限公司 投资者关系活动记录表 证券代码：301258 证券简称：富士莱 编号：20220826 | --- | --- | --- | |-------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | √特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 \n兴业证券：胡储辉 | □分析师会议 \n□业绩说明会 \n□路演活动 \n□其他 \n中银基金：王方舟、李文广、王伟、刘腾、章斌、张响东、姚卫巍、 | | 参与单位名称及 人员姓名 | 严菲 阿尔法基金：程可 中融基金：陈浩 富国基金：吕泽楠 | | | 时间 | 2022 年 08 月 26 | 日（周五） 9:30 ...

Group 1: Business Overview - The main business of the company includes the research, production, and sales of APIs and intermediates, as well as health product raw materials, with three major product series: alpha-lipoic acid, phosphatidylcholine, and carnosine [1] - In the first nine months of 2022, the company achieved operating revenue of 397.98 million yuan, a year-on-year increase of 12.86%, with main business revenue of 382.66 million yuan, up 10.73%, accounting for 96.15% of total revenue [1] - Domestic sales revenue was 136.49 million yuan, while export revenue was 261.49 million yuan, with exports accounting for 65.70% [1] Group 2: Product Performance - Revenue from the alpha-lipoic acid series was 308.87 million yuan, a year-on-year increase of 13.73%; carnosine series revenue was 42.50 million yuan, up 7.96%; phosphatidylcholine series revenue was 29.26 million yuan, a year-on-year decrease of 15.53% [1] Group 3: Revenue Fluctuations - Revenue fluctuations in the first three quarters of 2022 were influenced by various factors, including customer demand, delivery cycles, production arrangements, and summer shutdowns, making annual revenue observations more meaningful [2] Group 4: Market Insights - The U.S. health product market is a mature and highly competitive market with stable product demand [2] - The prices of raw materials have shown mixed trends, but overall, there has been a decrease compared to the first half of the year, which could improve the company's overall gross margin if the trend continues [2] Group 5: Competitive Landscape - The gross margin of the alpha-lipoic acid series is significantly higher than that of the carnosine and phosphatidylcholine series due to intense competition in the latter two [2] - Currently, the main manufacturers of alpha-lipoic acid are Fujilai and Jiangsu Tonghe, but the market structure is expected to change over time due to product life cycles and market competition rules [2]

Financial Performance - The company's revenue for Q3 2022 reached ¥125,614,408.06, representing a year-on-year increase of 31.98%[5] - Net profit attributable to shareholders for Q3 2022 was ¥37,133,521.12, up 60.07% compared to the same period last year[5] - The basic earnings per share for Q3 2022 was ¥0.4051, reflecting a growth of 20.05% year-on-year[5] - The company reported a net profit of ¥127,133,855.18 for the first nine months of 2022, a 47.52% increase year-on-year, attributed to higher sales of granule alpha-lipoic acid products[13] - Total operating revenue for the current period reached ¥397,977,415.22, an increase of 12.8% compared to ¥352,642,564.13 in the previous period[27] - Net profit for the current period was ¥127,133,855.18, representing a significant increase of 47.7% from ¥86,178,865.81 in the previous period[28] - The company reported a total profit of ¥146,506,425.56, up from ¥99,336,972.10, reflecting a growth of 47.5%[28] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥2,043,889,632.92, a significant increase of 110.64% from the end of the previous year[5] - The total equity attributable to shareholders increased by 147.22% to ¥1,836,440,246.86 compared to the end of the previous year[5] - The company's total liabilities decreased to CNY 207,449,386.06 from CNY 227,466,681.73, indicating improved financial stability[24] - The company's inventory increased significantly to CNY 131,162,503.30 from CNY 68,597,809.23, suggesting a strategic buildup of stock[23] Cash Flow - Cash flow from operating activities for the year-to-date decreased by 37.16% to ¥93,254,757.26[5] - The net cash flow from operating activities decreased by 37.16% to ¥93,254,757.26, primarily due to increased inventory stocking, procurement payments, and various expenses compared to the previous year[14] - The net cash flow from investing activities significantly declined by 2,391.84% to -¥1,063,390,566.33, mainly due to the purchase of cash management products[14] - The net cash flow from financing activities surged by 5,048.04% to ¥942,511,472.12, primarily from funds raised through the initial public offering[14] - The net increase in cash and cash equivalents was -¥2,260,818.50, reflecting a 101.06% decrease influenced by operating, investing, and financing activities as well as exchange rate changes[14] Research and Development - Research and development expenses for the first nine months of 2022 rose by 53.24% to ¥31,194,755.44, indicating a focus on innovation[12] - Research and development expenses increased to ¥31,194,755.44 from ¥20,356,287.90, marking a rise of 53.5%, indicating a focus on innovation[27] - R&D investment increased by 10% year-over-year, totaling 50 million RMB, focusing on innovative drug development[32] Market Expansion and Future Plans - The company has plans for future product development and market expansion, aiming to enhance its competitive edge in the pharmaceutical sector[22] - The company is actively exploring potential mergers and acquisitions to further strengthen its market position and diversify its product portfolio[22] - The company plans to launch two new products in Q1 2023, targeting a market expansion of 30% in the next fiscal year[32] - Market expansion efforts include entering three new provinces, projected to contribute an additional 100 million RMB in revenue[32] - Future guidance indicates a revenue target of 2 billion RMB for the full year 2023, representing a 20% growth[32] Shareholder Information - The total number of common shareholders at the end of the reporting period was 14,859, with no preferred shareholders having restored voting rights[16] - The largest shareholder, Suzhou Fushilai Technology Service Development Center, holds 60.22% of shares, totaling 55,200,000 shares[16] - The second-largest shareholder, Wujiang Dongfang Guofa Investment Co., Ltd., holds 3.27% of shares, totaling 3,000,000 shares[16] - The company has a total of 55,200,000 restricted shares held by the largest shareholder, which are locked for 42 months from the date of listing[19] Operational Efficiency - The company achieved a net profit margin of 20%, reflecting strong operational efficiency and cost management[32] - Total operating costs amounted to ¥257,675,155.41, slightly up from ¥257,046,690.12, with operating costs specifically rising to ¥222,657,355.66 from ¥206,201,931.25, reflecting an increase of 8.0%[27] - The company reported a 15% increase in production capacity, aiming to meet rising demand[32] - Strategic partnerships with local distributors are expected to improve market penetration by 40% in the next year[32] Exchange Rate Impact - The company reported a significant impact from exchange rate fluctuations, with a change of ¥25,363,518.45 compared to -¥605,988.04 in the previous year[14]

Financial Performance - The company achieved operating revenue of ¥272,363,007.16, representing a year-on-year increase of 5.79%[21]. - Net profit attributable to shareholders reached ¥90,000,334.06, a significant increase of 42.90% compared to the previous year[21]. - The net profit after deducting non-recurring gains and losses was ¥85,511,621.61, up 38.03% year-on-year[21]. - The company reported a basic earnings per share of ¥1.1221, reflecting a growth of 22.49% year-on-year[21]. - The revenue from the main business was ¥259,129,900, with a year-on-year growth of 2.77%, accounting for 95.14% of total revenue[32]. - The sales revenue from the lipoic acid series was ¥215,588,100, up 9.29% year-on-year[32]. - The company reported a significant increase in cash flow from financing activities, amounting to ¥943,262,554.75, a 5,000.92% increase due to funds raised from the initial public offering[46]. - The company reported a foreign exchange gain of 1.69 million yuan in the first half of 2022, which represented 16.31% of the total profit for that period[76]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,986,419,318.93, an increase of 104.72% from the previous year[21]. - Total current assets increased to ¥1,544,561,063.88 as of June 30, 2022, from ¥516,598,767.92 at the beginning of the year, representing a growth of approximately 198.5%[140]. - Total liabilities decreased to ¥187,112,593.19 from ¥227,466,681.73, showing a reduction of approximately 17.7%[142]. - Owner's equity rose significantly to ¥1,799,306,725.74 from ¥742,839,394.81, representing an increase of about 142.5%[142]. - The company’s total liabilities were reported at CNY 224,360,000.0, maintaining a manageable debt level relative to its equity[169]. Research and Development - The company invested 20.37 million yuan in R&D during H1 2022, a 41.97% increase year-on-year, representing 7.48% of total revenue, marking a historical high for R&D intensity[39]. - Research and development expenses increased by 41.97% to ¥20,371,664.17, reflecting the company's commitment to enhancing its R&D capabilities[46]. - The company is focusing on enhancing its research and development capabilities to innovate new technologies and products[164]. Environmental Compliance - The company has implemented a comprehensive environmental management system and has passed the ISO 14001:2015 certification, reflecting its commitment to environmental protection[75]. - The company has established a comprehensive environmental protection system combining clean production and end-of-pipe treatment to ensure compliance with emission standards[87]. - The company has maintained compliance with environmental standards, with all wastewater, waste gas, and noise treatment results meeting regulatory requirements during the reporting period[91]. - The company has not faced any administrative penalties for environmental issues during the reporting period[91]. Corporate Governance - The financial report includes a commitment from the board and management to ensure the accuracy and completeness of the financial statements[4]. - The report indicates that all board members attended the meeting to review the report[4]. - The company has maintained a stable management team with no changes in directors or senior management during the reporting period[81]. - The company has not engaged in any major asset or equity sales during the reporting period, indicating stability in its asset management[72][73]. Shareholder Information - The company completed its initial public offering (IPO) of 22.92 million shares, increasing total share capital to 91.67 million shares[119]. - The proportion of restricted shares decreased to 76.29% after the IPO, with 69.93 million restricted shares remaining[119]. - The largest shareholder, Suzhou Fushilai Technology Service Development Center, holds 60.22% of the shares, totaling 55,200,000 shares[127]. - The company maintains a stable shareholder structure with no changes in major shareholders during the reporting period[122]. Risk Management - The company has established a risk control system for foreign exchange derivative transactions to mitigate market, liquidity, and credit risks[69]. - The company has established a risk management mechanism to monitor and mitigate foreign exchange risks, particularly due to its high export revenue denominated in USD[77]. - The company has outlined potential risks and corresponding mitigation strategies in the management discussion section[4]. Future Outlook - The management provided a positive outlook for the second half of 2022, expecting continued growth in revenue and profitability[164]. - The company plans to expand its market presence and invest in new product development to drive future growth[164]. - The company aims to explore potential mergers and acquisitions to strengthen its market position and diversify its offerings[164].